If you are a Healthcare Professional and you would like to log in to access this content, please click "Login".
You are now leaving the Lilly Medical Web site
The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. Eli Lilly and Company does not control, influence, or endorse this site, and the opinions, claims or comments expressed on this site should not be attributed to Eli Lilly and Company. Eli Lilly and Company is not responsible for the privacy policy of any third party web sites. We encourage you to read the privacy policy of every web site you visit.
Menu closed
Please use a minimum of three unique search wordsOur search is configured to only display links relevant to answer your question. For the best results please use specific and relevant keywords that accurately reflect the information you are seeking.Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at UK: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.
Alimta ® (pemetrexed for injection)
This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information. Please refer to the link for full prescribing information:
Alimta Summary of Product Characteristics (SmPC)
Alimta® (pemetrexed): Infusion Via Central Line Versus Peripheral IV
Lilly does not have any information available regarding infusion of pemetrexed via a central line versus peripheral IV.
Detailed
Information
Pemetrexed
must be administered as an IV infusion.1
Lilly
has not studied central line vs peripheral IV administration of
pemetrexed.2
Clinical
circumstances may be present which prevent a patient from having
peripheral IV access. In the case of central line access only, the
treating physician should make an appropriate clinical decision
considering the risk/benefit, given that there is no information
available regarding administration of pemetrexed via a central line
IV.2
References
1.
Alimta [summary of product characteristics]. Eli Lilly Nederland
B.V., The Netherlands
2.
Data on file, Eli Lilly and Company and/or one of its subsidiaries.
Glossary
IV =
intravenous
Lilly
= Eli Lilly and Company
Date of Last Review:September 04, 2020
Are you satisfied with this content?
Contact Lilly
Call or Email us
If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at ukmedinfo@lilly.com